Copyright © 2002 by the European Society of Cardiology.
Effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized trial
a Oosterschelde Ziekenhuizen, Goes, The Netherlands
b University Hospital, Groningen, The Netherlands
Trial Coordination Centre (TCC), Groningen, The Netherlands
c Reinier de Graaf Gasthuis, Delft, The Netherlands
d Leyenburg Ziekenhuis, Den Haag, The Netherlands
e Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
revised April 16, 2002; accepted April 17, 2002
Abstract
Aims Residual ischaemia following acute myocardial infarction (AMI) is related to an adverse outcome, although the effect of early initiation of statin therapy is unknown.
Methods A randomized, placebo-controlled, double-blind, parallel study was performed, which compared fluvastatin 80mg daily with placebo in patients with an AMI and total cholesterol of <6·5mmol.l–1. Ischaemia was measured by ambulatory electrocardiographic (AECG) monitoring over 48-h at baseline, after 6 weeks and at 12 months.
Results Five hundred and forty patients were included (83% male, age 61±11 years); 43% had an anterior AMI and 50% were treated with fibrinolytics in the acute phase. After 12 months, the total cholesterol (TC) level was reduced by 13% and LDL-C (low-density-lipoprotein cholesterol) by 21% (from 3·5mmol.l–1 to 2·7mmol.l–1) in the fluvastatin treatment group. Both TC and LDL increased by 9% in the placebo group (P<0·001 between groups). At baseline, ischaemia on AECG was present in only 11% of patients, and absent in 77%; in the remaining 11%, recordings were technically inadequate. After 6 weeks, 32/48 (67%), and 12 months 35/46 (76%) of the patients with ischaemia on the baseline AECG, no longer showed signs of ischaemia. Nevertheless, ischaemia at baseline was predictive for the occurrence of any major clinical event (RR=2·35; 95% CI 1·39–3·2;P <0·001). Fluvastatin treatment did not affect ischaemia on AECG, nor the occurrence of any major clinical events as compared to placebo. Post-hoc analysis in patients with the most pronounced ischaemia at baseline showed a trend for a beneficial effect of fluvastatin on major clinical events (P=0·084).
Conclusion Residual ischaemia after AMI is observed less frequently in the present study, than in earlier studies, although it is predictive for future cardiovascular events. As a result, the present study was underpowered, and no effect of fluvastatin on AECG ischaemia, or major clinical events in the first year after AMI, could be detected. The present data do not confirm other reports which support widespread use of statin treatment early after AMI. Copyright 2002 The European Society of Cardiology. Published by Elsevier Science Ltd. All rights reserved.
Key Words: Myocardial ischaemia, acute coronary syndrome, fluvastatin, statin, ambulatory electrocardiographic monitoring.
f1 Correspondence: Prof. Dr D. J. van Veldhuisen, Department of Cardiology/Thoraxcenter, University Hospital Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands.
References
- Lancet. 1994;344:1383–1389[CrossRef][Web of Science][Medline]
- Sacks FM, Pfeffer MA, Moye LA. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001–1009
[Abstract/Free Full Text] - N Engl J Med. 1998;339:1349–1357
[Abstract/Free Full Text] - Deedwania PC, Carbajal EV. Ambulatory electrocardiography evaluation of asymptomatic, unstable, and stable coronary artery disease patients for myocardial ischemia. Cardiol Clin. 1992;10:417–430[Medline]
- Sharaf BL, Williams DO, Miele NJ. A detailed angiographic analysis of patients with ambulatory electrocardiographic ischemia: results from the Asymptomatic Cardiac Ischemia Pilot (ACIP) study angiographic core laboratory. J Am Coll Cardiol. 1997;29:78–84[Abstract]
- Ouyang P, Chandra NC, Gottlieb SO. Frequency and importance of silent myocardial ischemia identified with ambulatory electrocardiographic monitoring in the early in-hospital period after acute myocardial infarction. Am J Cardiol. 1990;65:267–270[CrossRef][Web of Science][Medline]
- Langer A, Minkowitz J, Dorian P. Pathophysiology and prognostic significance of Holter-detected ST segment depression after myocardial infarction. The Tissue Plasminogen Activator: Toronto (TPAT) Study Group. J Am Coll Cardiol. 1992;20:1313–1317[Abstract]
- Solimene MC, Ramires JA, Gruppi CJ. Prognostic significance of silent myocardial ischemia after a first uncomplicated myocardial infarction. Int J Cardiol. 1993;38:41–47[CrossRef][Web of Science][Medline]
- Silva P, Galli M, Campolo L. Prognostic significance of early ischemia after acute myocardial infarction in lowrisk patients. IRES (Ischemia Residua) Study Group. Am J Cardiol. 1993;71:1142–1147[CrossRef][Web of Science][Medline]
- Gill JB, Cairns JA, Roberts RS. Prognostic importance of myocardial ischemia detected by ambulatory monitoring early after acute myocardial infarction. N Engl J Med. 1996;334:65–70
[Abstract/Free Full Text] - Andrews TC, Raby K, Barry J. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation. 1997;95:324–328
[Abstract/Free Full Text] - van Boven AJ, Jukema JW, Zwinderman AH, Crijns HJ, Lie KI, Bruschke AV. Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. REGRESS Study Group. Circulation. 1996;94:1503–1505
[Abstract/Free Full Text] - Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA. 1998;279:1643–1650
[Abstract/Free Full Text] - Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med. 2000;6:1399–1402[CrossRef][Web of Science][Medline]
- Yokoyama I, Momomura S, Ohtake T. Improvement of impaired myocardial vasodilatation due to diffuse coronary atherosclerosis in hypercholesterolemics after lipid-lowering therapy. Circulation. 1999;100:117–122
[Abstract/Free Full Text] - Guethlin M, Kasel AM, Coppenrath K, Ziegler S, Delius W, Schwaiger M. Delayed response of myocardial flow reserve to lipid-lowering therapy with fluvastatin. Circulation. 1999;99:475–481
[Abstract/Free Full Text] - Rogers WJ, Bourassa MG, Andrews TC. Asymptomatic Cardiac Ischemia Pilot (ACIP) study: outcome at 1 year for patients with asymptomatic cardiac ischemia randomized to medical therapy or revascularization. The ACIP Investigators. J Am Coll Cardiol. 1995;26:594–605[Abstract]
- Lancet. 2001;357:995–1001[CrossRef][Web of Science][Medline]
- Fonarow GC, Gawlinski A. Rationale and design of the Cardiac Hospitalization Atherosclerosis Management Program at the University of California Los Angeles. Am J Cardiol. 2000;85:10A–17A[Web of Science][Medline]
- Aronow HD, Topol EJ, Roe MT. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet. 2001;357:1063–1068[CrossRef][Web of Science][Medline]
- Heeschen C, Hamm CW, Laufs U, Snapinn S, Bohm M, White HD. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation. 2002;105:1446–1452
[Abstract/Free Full Text] - Schwartz GG, Olsson AG, Ezekowitz MD. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711–1718
[Abstract/Free Full Text]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. P. Morrissey, G. A. Diamond, and S. Kaul Statins in Acute Coronary Syndromes: Do the Guideline Recommendations Match the Evidence? J. Am. Coll. Cardiol., October 6, 2009; 54(15): 1425 - 1433. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. SHISHEHBOR and S. L. HAZEN JUPITER to Earth: A statin helps people with normal LDL-C and high hs-CRP, but what does it mean? Cleveland Clinic Journal of Medicine, January 1, 2009; 76(1): 37 - 44. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. G. P. Roberts, E. Guallar, and A. Rodriguez Efficacy and Safety of Statin Monotherapy in Older Adults: A Meta-Analysis J. Gerontol. A Biol. Sci. Med. Sci., August 1, 2007; 62(8): 879 - 887. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. K Choudhry, R. Levin, and W. C Winkelmayer Statins in elderly patients with acute coronary syndrome: an analysis of dose and class effects in typical practice Heart, August 1, 2007; 93(8): 945 - 951. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Nogueira and M. Weir The Unique Character of Cardiovascular Disease in Chronic Kidney Disease and Its Implications for Treatment with Lipid-Lowering Drugs Clin. J. Am. Soc. Nephrol., July 1, 2007; 2(4): 766 - 785. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. N. Patel, M. H. Shishehbor, and D. L. Bhatt A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis Eur. Heart J., March 2, 2007; 28(6): 664 - 672. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Hulten, J. L. Jackson, K. Douglas, S. George, and T. C. Villines The Effect of Early, Intensive Statin Therapy on Acute Coronary Syndrome: A Meta-analysis of Randomized Controlled Trials. Arch Intern Med, September 25, 2006; 166(17): 1814 - 1821. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Briel, G. G. Schwartz, P. L. Thompson, J. A. de Lemos, M. A. Blazing, G.-A. van Es, M. Kayikcioglu, H.-R. Arntz, F. R. den Hartog, N. J. G. M. Veeger, et al. Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials. JAMA, May 3, 2006; 295(17): 2046 - 2056. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. C. Fonarow In-Hospital Initiation of Statin Therapy in Acute Coronary Syndromes: Maximizing the Early and Long-term Benefits Chest, November 1, 2005; 128(5): 3641 - 3651. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. D. Varosy and D. D. Waters Do statins confer early benefit after acute coronary syndromes? The results from FLORIDA Eur. Heart J., December 2, 2002; 23(24): 1893 - 1896. [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||